Literature DB >> 16140280

A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters.

Georgianna G Gould1, Alfonso V Altamirano, Martin A Javors, Alan Frazer.   

Abstract

BACKGROUND: Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT. Serotonergic effects occur with lower doses, whereas both serotonergic and noradrenergic effects occur with higher doses of venlafaxine. Chronic treatment of rats with selective serotonin reuptake inhibitors decreases SERT binding sites, whereas similar treatment with selective norepinephrine reuptake inhibitors decreases NET binding sites. We hypothesized that venlafaxine would affect monoamine transporters dose-dependently, with low doses causing selective reduction of SERT binding sites and higher doses reducing both SERT and NET binding sites.
METHODS: Rats were treated for 21 days with a low (15 mg/kg/day) or high (70 mg/kg/day) dose of venlafaxine, vehicle, or other antidepressants. The SERT and NET density was determined by quantitative autoradiography.
RESULTS: Neither dose of venlafaxine nor amitriptyline reduced binding to either the SERT or NET. In rats with noradrenergic terminals destroyed by 6-hydroxydopamine, venlafaxine still failed to reduce SERT binding. Also, rats treated simultaneously with sertraline plus desipramine exhibited reductions in both SERT and NET binding.
CONCLUSIONS: Chronic venlafaxine treatment affected SERT and NET binding differently from paroxetine or desipramine. The inability of venlafaxine to reduce SERT or NET binding sites is not due to its dual uptake inhibiting properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140280     DOI: 10.1016/j.biopsych.2005.07.011

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  12 in total

1.  A case of amelioration of venlafaxine-discontinuation "brain shivers" with atomoxetine.

Authors:  Jose A Cortes; Rajiv Radhakrishnan
Journal:  Prim Care Companion CNS Disord       Date:  2013

Review 2.  Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.

Authors:  Lynette C Daws; Georgianna G Gould
Journal:  Pharmacol Ther       Date:  2011-04-05       Impact factor: 12.310

3.  Differential regulation of serotonin-1A receptor-stimulated [35S]GTP gamma S binding in the dorsal raphe nucleus by citalopram and escitalopram.

Authors:  Dania V Rossi; Teresa F Burke; Julie G Hensler
Journal:  Eur J Pharmacol       Date:  2008-02-05       Impact factor: 4.432

4.  Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs.

Authors:  Zaorui Zhao; Han-Ting Zhang; Elianna Bootzin; Mark J Millan; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

5.  Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine.

Authors:  Zaorui Zhao; Alicia M Baros; Han-Ting Zhang; M Danet S Lapiz; Corina O Bondi; David A Morilak; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-04-16       Impact factor: 7.853

6.  In vivo effect of antidepressants on [3H]paroxetine binding to serotonin transporters in rat brain.

Authors:  Subhash M Nadgir; Manish Malviya
Journal:  Neurochem Res       Date:  2008-04-25       Impact factor: 3.996

7.  Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain.

Authors:  Yukie Kawahara; Hiroshi Kawahara; Fumi Kaneko; Masatoshi Tanaka
Journal:  Psychopharmacology (Berl)       Date:  2007-05-30       Impact factor: 4.530

8.  Combined norepinephrine/serotonergic reuptake inhibition: effects on maternal behavior, aggression, and oxytocin in the rat.

Authors:  Elizabeth Thomas Cox; Thomas Merryfield Jarrett; Matthew Stephen McMurray; Kevin Greenhill; Vivian E Hofler; Sarah Kaye Williams; Paul Wayland Joyner; Christopher L Middleton; Cheryl H Walker; Josephine M Johns
Journal:  Front Psychiatry       Date:  2011-06-08       Impact factor: 4.157

9.  Neuropeptide Trefoil Factor 3 Reverses Depressive-Like Behaviors by Activation of BDNF-ERK-CREB Signaling in Olfactory Bulbectomized Rats.

Authors:  Jiali Li; Yixiao Luo; Ruoxi Zhang; Haishui Shi; Weili Zhu; Jie Shi
Journal:  Int J Mol Sci       Date:  2015-11-30       Impact factor: 5.923

10.  Meta-analysis of molecular imaging of serotonin transporters in major depression.

Authors:  Gregor Gryglewski; Rupert Lanzenberger; Georg S Kranz; Paul Cumming
Journal:  J Cereb Blood Flow Metab       Date:  2014-05-07       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.